Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers
Monica Margoni, Paolo Preziosa, Paola Tortorella, Massimo Filippi, Maria A. Rocca
Topics & Concepts
OcrelizumabMedicineMultiple sclerosisNeurologyNeurodegenerationAmyotrophic lateral sclerosisImmunologyDiseaseRituximabPathologyAntibodyPsychiatryMultiple Sclerosis Research StudiesNeuroinflammation and Neurodegeneration MechanismsPeripheral Neuropathies and Disorders